Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Autolus Therapeutics stock

AUTL
US05280R1005
A2JNZJ

Price

1.40
Today +/-
+0
Today %
+0 %

Autolus Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Autolus Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Autolus Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Autolus Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Autolus Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Autolus Therapeutics Stock Price History

DateAutolus Therapeutics Price
4/16/20251.40 undefined
4/16/20251.40 undefined
4/15/20251.45 undefined
4/14/20251.33 undefined
4/11/20251.36 undefined
4/11/20251.40 undefined
4/10/20251.19 undefined
4/9/20251.35 undefined
4/8/20251.25 undefined
4/7/20251.34 undefined
4/4/20251.40 undefined
4/3/20251.51 undefined
4/2/20251.61 undefined
4/1/20251.41 undefined
3/31/20251.53 undefined
3/28/20251.67 undefined
3/27/20251.69 undefined
3/26/20251.64 undefined
3/25/20251.63 undefined
3/24/20251.71 undefined
3/21/20251.73 undefined
3/19/20251.68 undefined
3/18/20251.94 undefined

Autolus Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Autolus Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Autolus Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Autolus Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Autolus Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Autolus Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Autolus Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Autolus Therapeutics’s growth potential.

Autolus Therapeutics Revenue, EBIT and net profit per share

DateAutolus Therapeutics RevenueAutolus Therapeutics EBITAutolus Therapeutics Net Income
2030e574.81 M undefined0 undefined233.45 M undefined
2029e593.02 M undefined217.02 M undefined173.73 M undefined
2028e444.23 M undefined53.12 M undefined-27.96 M undefined
2027e309.81 M undefined-27.51 M undefined-155.54 M undefined
2026e123.05 M undefined-215.54 M undefined-219.44 M undefined
2025e38.23 M undefined-240.18 M undefined-239.81 M undefined
202410.12 M undefined-240.79 M undefined-220.66 M undefined
20231.7 M undefined-175.53 M undefined-208.38 M undefined
20226.36 M undefined-167.53 M undefined-148.84 M undefined
20212.33 M undefined-164.32 M undefined-142.1 M undefined
20201.72 M undefined-168.15 M undefined-142.09 M undefined
20192.91 M undefined-141.96 M undefined-123.85 M undefined
20181.41 M undefined-57.53 M undefined-44.75 M undefined
20171.69 M undefined-23.42 M undefined-19.73 M undefined
20161.21 M undefined-14.38 M undefined-12.55 M undefined
20151.21 M undefined-14.38 M undefined-12.55 M undefined

Autolus Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
1111212611038123309444593574
----100.00-50.00100.00200.00-83.33900.00280.00223.68151.2243.6933.56-3.20
----------------
0000000000000000
-12-12-19-44-123-142-142-148-208-220-239-219-155-27173233
--58.33131.58179.5515.45-4.2340.545.778.64-8.37-29.22-82.58-740.7434.68
38.7938.7938.7931.5643.0751.5672.0894.99173.94255.16000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Autolus Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Autolus Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2015201620172018201920202021202220232024
                   
28.1137.1247.1217.5210.6153.3310.3382.4239.57588.02
00000000.10.112.58
000000028.924.4345.66
0000000004.14
0.70.72.92.28.11410.414.311.1920.53
28.8137.8250219.7218.7167.3320.7425.7275.3660.93
3.36.213.52051.689.752.358.495.65105.05
0000000000
0000000000
000.400.30.20.10012.37
0000000000
0001.32.57.46.26.14.434.37
3.36.213.921.354.497.358.664.5100.08121.8
32.1144263.9241273.1264.6379.3490.2375.38782.73
                   
00100100100100100100126130
0.060.190.360.360.50.60.841.011.021.56
-28.2-47.9-92.7-113.3-237.2-379.2-521.3-670.2-878.56-1,099.22
-4.7-3.8-9.9-15.5-8.7-5.9-8.6-38.9-28.99-29.17
0000000000
30.6142.7255.4232.6254.8210313.3298.6111.47427.33
1.41.9321.12.30.40.50.11.97
12.513.51822.830.92845.444.6355.27
0.30.60.61.11.10.50.20.40.533.5
0000000000
0000000000
2.7517.121.12533.728.646.345.2760.74
00000000170.9244.6
0000000000
0.810.60.523.750.663.7145.248.2750.06
0.810.60.523.750.663.7145.2219.17294.66
3.5617.721.648.784.392.3191.5264.44355.4
34.1148.7273.1254.2303.5294.3405.6490.1375.91782.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Autolus Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Autolus Therapeutics's financial health and stability.

Assets

Autolus Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Autolus Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Autolus Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Autolus Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (k)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2015201620172018201820192020202120222023
-19-19-12-44-20-123-142-142-148-208
1101045876
000000-1000
00-14-3-161430
5561336438213768
0000000000
000001,0001,000000
-16-16-9-31-19-101-117-117-112-145
-2-2-1-9-4-18-14-8-10-10
-2-2-1-9-4-18-14-8-10-10
0000000000
0000000000
0000000000
127127321560108742461630
127127321560108742842230
000000038590
0000000000
10910917110-29-6-5715672-142
-19.24-19.24-11.71-41.07-24.21-120.15-132.44-126.72-123.15-156.57
0000000000

Autolus Therapeutics stock margins

The Autolus Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Autolus Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Autolus Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Autolus Therapeutics's sales revenue. A higher gross margin percentage indicates that the Autolus Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Autolus Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Autolus Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Autolus Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Autolus Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Autolus Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Autolus Therapeutics Margin History

Autolus Therapeutics Gross marginAutolus Therapeutics Profit marginAutolus Therapeutics EBIT marginAutolus Therapeutics Profit margin
2030e-6.37 %0 %40.61 %
2029e-6.37 %36.6 %29.3 %
2028e-6.37 %11.96 %-6.29 %
2027e-6.37 %-8.88 %-50.21 %
2026e-6.37 %-175.17 %-178.33 %
2025e-6.37 %-628.29 %-627.34 %
2024-6.37 %-2,379.34 %-2,180.45 %
2023-6.37 %-10,337.34 %-12,272.26 %
2022-6.37 %-2,634.12 %-2,340.25 %
2021-6.37 %-7,052.36 %-6,098.71 %
2020-6.37 %-9,776.16 %-8,261.05 %
2019-6.37 %-4,878.35 %-4,256.01 %
2018-6.37 %-4,080.14 %-3,173.76 %
2017-6.37 %-1,385.8 %-1,167.46 %
2016-6.37 %-1,188.43 %-1,037.19 %
2015-6.37 %-1,188.43 %-1,037.19 %

Autolus Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Autolus Therapeutics earnings per share therefore indicates how much revenue Autolus Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Autolus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Autolus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Autolus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Autolus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Autolus Therapeutics Revenue, EBIT and net profit per share

DateAutolus Therapeutics Sales per ShareAutolus Therapeutics EBIT per shareAutolus Therapeutics Earnings per Share
2030e2.16 undefined0 undefined0.88 undefined
2029e2.23 undefined0 undefined0.65 undefined
2028e1.67 undefined0 undefined-0.11 undefined
2027e1.16 undefined0 undefined-0.58 undefined
2026e0.46 undefined0 undefined-0.82 undefined
2025e0.14 undefined0 undefined-0.9 undefined
20240.04 undefined-0.94 undefined-0.86 undefined
20230.01 undefined-1.01 undefined-1.2 undefined
20220.07 undefined-1.76 undefined-1.57 undefined
20210.03 undefined-2.28 undefined-1.97 undefined
20200.03 undefined-3.26 undefined-2.76 undefined
20190.07 undefined-3.3 undefined-2.88 undefined
20180.04 undefined-1.82 undefined-1.42 undefined
20170.04 undefined-0.6 undefined-0.51 undefined
20160.03 undefined-0.37 undefined-0.32 undefined
20150.03 undefined-0.37 undefined-0.32 undefined

Autolus Therapeutics business model

Autolus Therapeutics PLC is a global biopharmaceutical company dedicated to the development of novel therapies for cancer. The company was founded in 2014 by an experienced team of scientists and executives from the biotech industry with the goal of revolutionizing cancer treatment. Autolus Therapeutics' business model is to develop and market novel cancer immunotherapies. The company utilizes innovative technologies such as CAR-T cell therapy and T-cell receptor (TCR) therapy. By targeting the immune system, cancer cells can be recognized and destroyed. Autolus Therapeutics operates a complex network of different sectors and areas to ensure comprehensive development and marketing of its products. This includes research and development, manufacturing and production, as well as clinical testing and approval of therapies. Currently, Autolus Therapeutics focuses on developing therapies for various types of cancer, such as leukemia, lymphoma, and solid tumors. The company has built a broad pipeline of products and therapeutic approaches that are currently in different phases of clinical development. The main focus is on an innovative CAR-T cell therapy, in which the body's own T cells are equipped with a chimeric antigen receptor (CAR) to specifically recognize and combat cancer cells. Autolus Therapeutics' different CAR-T therapies target specific antigens expressed on tumor cells. Another important part of Autolus Therapeutics' pipeline is T-cell receptor (TCR) therapies. T cells are equipped with specific receptors to also target and destroy cancer cells. These therapeutic approaches are currently in clinical development. Autolus Therapeutics collaborates closely with other companies and institutions in the industry to further advance the development and marketing of cancer therapies. This includes strategic partnerships with major pharmaceutical companies such as AstraZeneca and Bluebird Bio. The history of Autolus Therapeutics is characterized by rapid growth and high innovation. Shortly after its founding, the company was able to secure significant funding rounds and international partners. In the following years, the pipeline was further expanded, and the first clinical trials were initiated. Currently, Autolus Therapeutics employs over 250 people at locations in the United Kingdom and the United States. The company has a market capitalization of around $1.5 billion and is considered one of the most promising companies in the biopharmaceutical industry. In summary, Autolus Therapeutics is an innovative and ambitious company dedicated to the research and development of novel cancer therapies. The broad pipeline of products and therapeutic approaches, as well as the close partnerships in the industry, give hope for a promising future of the company. Autolus Therapeutics is one of the most popular companies on Eulerpool.com.

Autolus Therapeutics SWOT Analysis

Strengths

Autolus Therapeutics PLC possesses several strengths that contribute to its competitive advantage in the market:

  • Strong pipeline: Autolus has a robust pipeline of innovative cell therapies targeting various types of cancer, which demonstrates its potential for long-term growth and revenue generation.
  • Strategic partnerships: The company has formed strategic partnerships with leading pharmaceutical companies, providing access to additional financial resources, expertise, and market opportunities.
  • Experienced management team: Autolus is led by a highly experienced management team with expertise in the field of cell therapy, ensuring effective decision-making and execution of the company's strategies.
  • Advanced technology: The company utilizes advanced gene editing and engineering technologies, enabling the development of next-generation cell therapies with improved efficacy and safety profiles.

Despite its strengths, Autolus Therapeutics PLC faces certain weaknesses that could hamper its growth and competitiveness:

  • Dependence on partnerships: The company heavily relies on partnerships for financial support and market access, which exposes it to potential risks such as partnership dissolution or dependency on others' decisions.
  • Limited product portfolio: Autolus currently has a relatively limited number of products in its portfolio, which may limit its revenue potential compared to competitors with broader offerings.
  • Regulatory challenges: The cell therapy industry is subject to stringent regulatory processes and requirements, which could cause delays in product approvals or limit market access for Autolus.

Autolus Therapeutics PLC can capitalize on various opportunities to expand its market presence and enhance its competitive position:

  • Increasing demand for innovative therapies: The growing demand for novel and effective cancer treatments presents a significant opportunity for Autolus to capitalize on its advanced cell therapies.
  • Expanding into new markets: Autolus can explore expansion opportunities in emerging markets, where there is a rising prevalence of cancer and a need for advanced treatment options.
  • Continued research and development: The company can invest in further research and development to expand its product portfolio, targeting additional indications or addressing unmet medical needs.
  • Strategic collaborations: Collaborating with academic institutions or research organizations can enhance Autolus' capabilities and provide access to new technologies or scientific advancements.

Autolus Therapeutics PLC faces certain threats that may impact its growth and competitiveness in the market:

  • Intense competition: The biopharmaceutical industry, particularly the field of cell therapy, is highly competitive, with the presence of established companies and emerging startups competing for market share.
  • Technological advancements by competitors: The rapid pace of technological advancements by competitors may result in the development of more effective and efficient cell therapies, potentially overshadowing Autolus' offerings.
  • Intellectual property risks: Autolus operates in an industry where intellectual property and patent protection are crucial. Any infringement claims or challenges to its intellectual property rights could impact the company's market position.
  • Stringent regulatory landscape: Regulatory changes or stricter regulatory requirements in the cell therapy industry may pose challenges for Autolus in obtaining necessary approvals, leading to delays or increased costs.

Weaknesses

Despite its strengths, Autolus Therapeutics PLC faces certain weaknesses that could hamper its growth and competitiveness:

  • Dependence on partnerships: The company heavily relies on partnerships for financial support and market access, which exposes it to potential risks such as partnership dissolution or dependency on others' decisions.
  • Limited product portfolio: Autolus currently has a relatively limited number of products in its portfolio, which may limit its revenue potential compared to competitors with broader offerings.
  • Regulatory challenges: The cell therapy industry is subject to stringent regulatory processes and requirements, which could cause delays in product approvals or limit market access for Autolus.

Autolus Therapeutics PLC can capitalize on various opportunities to expand its market presence and enhance its competitive position:

  • Increasing demand for innovative therapies: The growing demand for novel and effective cancer treatments presents a significant opportunity for Autolus to capitalize on its advanced cell therapies.
  • Expanding into new markets: Autolus can explore expansion opportunities in emerging markets, where there is a rising prevalence of cancer and a need for advanced treatment options.
  • Continued research and development: The company can invest in further research and development to expand its product portfolio, targeting additional indications or addressing unmet medical needs.
  • Strategic collaborations: Collaborating with academic institutions or research organizations can enhance Autolus' capabilities and provide access to new technologies or scientific advancements.

Autolus Therapeutics PLC faces certain threats that may impact its growth and competitiveness in the market:

  • Intense competition: The biopharmaceutical industry, particularly the field of cell therapy, is highly competitive, with the presence of established companies and emerging startups competing for market share.
  • Technological advancements by competitors: The rapid pace of technological advancements by competitors may result in the development of more effective and efficient cell therapies, potentially overshadowing Autolus' offerings.
  • Intellectual property risks: Autolus operates in an industry where intellectual property and patent protection are crucial. Any infringement claims or challenges to its intellectual property rights could impact the company's market position.
  • Stringent regulatory landscape: Regulatory changes or stricter regulatory requirements in the cell therapy industry may pose challenges for Autolus in obtaining necessary approvals, leading to delays or increased costs.

Opportunities

Autolus Therapeutics PLC can capitalize on various opportunities to expand its market presence and enhance its competitive position:

  • Increasing demand for innovative therapies: The growing demand for novel and effective cancer treatments presents a significant opportunity for Autolus to capitalize on its advanced cell therapies.
  • Expanding into new markets: Autolus can explore expansion opportunities in emerging markets, where there is a rising prevalence of cancer and a need for advanced treatment options.
  • Continued research and development: The company can invest in further research and development to expand its product portfolio, targeting additional indications or addressing unmet medical needs.
  • Strategic collaborations: Collaborating with academic institutions or research organizations can enhance Autolus' capabilities and provide access to new technologies or scientific advancements.

Autolus Therapeutics PLC faces certain threats that may impact its growth and competitiveness in the market:

  • Intense competition: The biopharmaceutical industry, particularly the field of cell therapy, is highly competitive, with the presence of established companies and emerging startups competing for market share.
  • Technological advancements by competitors: The rapid pace of technological advancements by competitors may result in the development of more effective and efficient cell therapies, potentially overshadowing Autolus' offerings.
  • Intellectual property risks: Autolus operates in an industry where intellectual property and patent protection are crucial. Any infringement claims or challenges to its intellectual property rights could impact the company's market position.
  • Stringent regulatory landscape: Regulatory changes or stricter regulatory requirements in the cell therapy industry may pose challenges for Autolus in obtaining necessary approvals, leading to delays or increased costs.

Threats

Autolus Therapeutics PLC faces certain threats that may impact its growth and competitiveness in the market:

  • Intense competition: The biopharmaceutical industry, particularly the field of cell therapy, is highly competitive, with the presence of established companies and emerging startups competing for market share.
  • Technological advancements by competitors: The rapid pace of technological advancements by competitors may result in the development of more effective and efficient cell therapies, potentially overshadowing Autolus' offerings.
  • Intellectual property risks: Autolus operates in an industry where intellectual property and patent protection are crucial. Any infringement claims or challenges to its intellectual property rights could impact the company's market position.
  • Stringent regulatory landscape: Regulatory changes or stricter regulatory requirements in the cell therapy industry may pose challenges for Autolus in obtaining necessary approvals, leading to delays or increased costs.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Autolus Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Autolus Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Autolus Therapeutics shares outstanding

The number of shares was Autolus Therapeutics in 2024 — This indicates how many shares 255.161 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Autolus Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Autolus Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Autolus Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Autolus Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Autolus Therapeutics.

Autolus Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2024-0.21 -0.1  (52.34 %)2024 Q4
9/30/2024-0.22 -0.31  (-41.81 %)2024 Q3
6/30/2024-0.2 -0.22  (-11 %)2024 Q2
3/31/2024-0.06 -0.24  (-327.81 %)2024 Q1
12/31/2023-0.26 -0.45  (-74.69 %)2023 Q4
9/30/2023-0.26 -0.26  (-1.96 %)2023 Q3
6/30/2023-0.23 -0.26  (-13.64 %)2023 Q2
3/31/2023-0.27 -0.23  (15.32 %)2023 Q1
12/31/2022-0.27 -0.23  (16.09 %)2022 Q4
9/30/2022-0.47 -0.47  (0.99 %)2022 Q3
1
2
3

Autolus Therapeutics shareholders

%
Name
Stocks
Change
Date
12.52521 % BioNTech SE33,333,33333,333,3332/13/2024
11.54885 % Syncona Investment Management Limited30,734,95730,734,9579/30/2024
9.52380 % Wellington Management Company, LLP25,345,6801,125,45412/31/2024
7.69760 % Clarus Ventures, LLC20,485,611012/31/2024
6.25285 % Syncona Portfolio Ltd16,640,720-1,913,90412/31/2024
5.63634 % Qatar Investment Authority15,000,00002/29/2024
5.55453 % PPF Group N.V.14,782,275170,00010/24/2024
5.34284 % Deep Track Capital LP14,218,903-1,053,26912/31/2024
4.01268 % Fidelity Management & Research Company LLC10,678,957-2,452,43612/31/2024
3.72399 % Avoro Capital Advisors LLC9,910,642-2,435,03612/31/2024
1
2
3
4
5
...
10

Autolus Therapeutics Executives and Management Board

Dr. Christian Itin

(59)
Autolus Therapeutics Chief Executive Officer, Executive Director (since 2016)
Compensation 2.15 M

Mr. William Young

(78)
Autolus Therapeutics Non-Executive Independent Director
Compensation 102,863

Ms. Linda Bain

(53)
Autolus Therapeutics Non-Executive Independent Director
Compensation 80,831

Ms. Cynthia Butitta

(69)
Autolus Therapeutics Non-Executive Independent Director
Compensation 74,374

Mr. John Berriman

(74)
Autolus Therapeutics Non-Executive Independent Director
Compensation 72,586
1
2
3
4

Autolus Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AbCellera Biolog Stock
AbCellera Biolog
SupplierCustomer-0,510,810,710,910,86
1

Most common questions regarding Autolus Therapeutics

What values and corporate philosophy does Autolus Therapeutics represent?

Autolus Therapeutics PLC represents a commitment to advancing the field of cell therapy and transforming the lives of patients with cancer. The company's corporate philosophy is centered around innovation, collaboration, and patient-centricity. Autolus Therapeutics PLC strives to develop and commercialize next-generation, precision-engineered T cell therapies to treat hematological malignancies and solid tumors. Their dedication to scientific excellence, cutting-edge research, and strategic partnerships enables them to create novel therapies with the potential to revolutionize cancer treatment. Through their unwavering focus on improving patient outcomes, Autolus Therapeutics PLC is shaping the future of cancer care.

In which countries and regions is Autolus Therapeutics primarily present?

Autolus Therapeutics PLC is primarily present in multiple countries and regions across the globe. The company operates in the United States, where it has its headquarters and a significant presence. Autolus Therapeutics also has a strong presence in the United Kingdom, as it originated from the University of London. Additionally, Autolus Therapeutics has expanded its reach to other European countries such as Germany, France, and Switzerland. The company's commitment to delivering innovative cell therapies has allowed it to establish a global footprint, continuously exploring opportunities to expand its presence in different regions worldwide.

What significant milestones has the company Autolus Therapeutics achieved?

Autolus Therapeutics PLC, a leading clinical-stage biopharmaceutical company, has achieved several significant milestones. The company has successfully advanced its autologous CAR-T cell therapies for the treatment of cancer. Notably, Autolus Therapeutics received Investigational New Drug (IND) approvals from regulatory authorities, allowing them to initiate multiple clinical trials for their innovative therapies. Furthermore, the company has achieved positive clinical data and demonstrated encouraging results in patients with various types of cancer. Autolus Therapeutics' relentless dedication to advancing these therapies underscores their commitment to revolutionizing cancer treatment and improving patient outcomes.

What is the history and background of the company Autolus Therapeutics?

Autolus Therapeutics PLC is a renowned biopharmaceutical company with a strong focus on developing innovative treatments for cancer patients. Founded in 2014, Autolus Therapeutics PLC has been at the forefront of advancing T-cell therapies to revolutionize cancer treatment. The company specializes in the development of next-generation, programmed T-cell therapies using its proprietary advanced cell programming technology. With a team of experts and collaborations worldwide, Autolus Therapeutics PLC is committed to delivering safe, effective, and individualized therapies to improve patient outcomes. Autolus Therapeutics PLC has achieved significant milestones and continues to make groundbreaking advancements in the field of oncology.

Who are the main competitors of Autolus Therapeutics in the market?

The main competitors of Autolus Therapeutics PLC in the market include other companies specializing in cell and gene therapy, such as bluebird bio, CRISPR Therapeutics, and Juno Therapeutics. These companies also focus on developing innovative treatments for cancer and other serious diseases by utilizing similar technologies. Autolus Therapeutics PLC competes in the market by leveraging its unique platforms and therapeutic approaches to bring next-generation cell therapies.

In which industries is Autolus Therapeutics primarily active?

Autolus Therapeutics PLC is primarily active in the biotechnology and healthcare industries. As a leading biopharmaceutical company, Autolus Therapeutics focuses on developing and commercializing innovative treatments in the field of immunotherapy. Specializing in the development of next-generation T cell therapies, Autolus Therapeutics aims to revolutionize cancer treatment by harnessing the power of the patient's immune system. With a commitment to advancing breakthrough therapies and improving patient outcomes, Autolus Therapeutics PLC plays a pivotal role in the biotechnology and healthcare sectors.

What is the business model of Autolus Therapeutics?

The business model of Autolus Therapeutics PLC focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Autolus Therapeutics PLC aims to harness the power of the immune system by engineering T-cells to recognize and kill cancer cells. By utilizing its proprietary technology platforms, Autolus Therapeutics PLC strives to create innovative and personalized treatment options for patients, with the goal of enhancing their outcomes and quality of life.

What is the P/E ratio of Autolus Therapeutics 2025?

The Autolus Therapeutics P/E ratio is -1.49.

What is the P/S ratio of Autolus Therapeutics 2025?

The Autolus Therapeutics P/S ratio is 9.35.

What is the Quality Investing of Autolus Therapeutics?

The Quality Investing for Autolus Therapeutics is 4/10.

What is the revenue of Autolus Therapeutics 2025?

The expected Autolus Therapeutics revenue is 38.23 M USD.

How high is the profit of Autolus Therapeutics 2025?

The expected Autolus Therapeutics profit is -239.81 M USD.

What is the business model of Autolus Therapeutics

Autolus Therapeutics PLC is a company specializing in the development of CAR-T cell therapies. Their mission is to combat life-threatening diseases with innovative therapies and improve patients' quality of life. The business model of Autolus is divided into several areas. The first area is the research and development of new therapies. Autolus is able to develop new therapies through extensive clinical studies and research findings. They use state-of-the-art technologies and methods to explore the potential of CAR-T cell therapies. Another important element of Autolus' business model is production and commercialization. The company produces the therapies in their own facilities and works closely with other companies to bring their products to market. Their therapies are approved by regulatory authorities worldwide and used by doctors to treat patients. Another branch of the business is collaboration with other companies. Autolus works closely with other research organizations and pharmaceutical companies to develop new therapies. The exchange of knowledge and technology is of great importance in this regard. Autolus also offers products based on CAR-T technology. These products are an important part of their business model and contribute to their success. The products range from new cancer therapies to specific treatments for certain hematological disorders. The company holds several patents on therapies that could disrupt the therapy market. Autolus also aims for a global presence and plans to sell its products worldwide. Autolus' business model is based on a strong internal research department capable of developing innovative CAR-T cell therapies. The company works closely with other pharmaceutical companies to bring its therapies to market. A key aspect of the business model is the continuous research and development of new therapies to harness the potential of CAR-T cell technology. Overall, the business model of Autolus Therapeutics PLC is focused on the production of innovative technology and improving the treatment of life-threatening diseases. The company has a strong presence in the therapy market and aims to strengthen and expand its position.

What is the Autolus Therapeutics dividend?

Autolus Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Autolus Therapeutics pay dividends?

The dividend cannot currently be calculated for Autolus Therapeutics or the company does not pay out a dividend.

What is the Autolus Therapeutics ISIN?

The ISIN of Autolus Therapeutics is US05280R1005.

What is the Autolus Therapeutics WKN?

The WKN of Autolus Therapeutics is A2JNZJ.

What is the Autolus Therapeutics ticker?

The ticker of Autolus Therapeutics is AUTL.

How much dividend does Autolus Therapeutics pay?

Over the past 12 months, Autolus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Autolus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Autolus Therapeutics?

The current dividend yield of Autolus Therapeutics is .

When does Autolus Therapeutics pay dividends?

Autolus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Autolus Therapeutics?

Autolus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Autolus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Autolus Therapeutics located?

Autolus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Autolus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Autolus Therapeutics from 4/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/17/2025.

When did Autolus Therapeutics pay the last dividend?

The last dividend was paid out on 4/17/2025.

What was the dividend of Autolus Therapeutics in the year 2024?

In the year 2024, Autolus Therapeutics distributed 0 USD as dividends.

In which currency does Autolus Therapeutics pay out the dividend?

The dividends of Autolus Therapeutics are distributed in USD.

All fundamentals about Autolus Therapeutics

Our stock analysis for Autolus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Autolus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.